Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Latest News about Agile Therapeutics

Recent news which mentions Agile Therapeutics

Agile Therapeutics Posts Growth In Third Quarter Results, Reiterates Confidence In Target of $25M Net Revenue, Positive Cash Flow In 2024
Tickers AGRX
Tags Health Care Penny Stocks Benzinga
From Benzinga
Agile Therapeutics (NASDAQ: AGRX) Upgraded To "Buy" Rating By Analysts At Maxim Group
Tickers AGRX
Tags General Market News Markets
From Benzinga
Agile Says It's On Track To Hit $25-$30 Million Net Annual Revenue After A Strong Performance In Its Second Quarter
Tickers AGRX
Tags News Benzinga Penny Stocks
From Benzinga
This Reproductive Health Company's Weekly Contraceptive Patch Can Reach Millions Of Women Thanks To A Partnership With Afaxys
Tickers AGRX
Tags Partner Content Afaxys Pharma Market News
From Benzinga
Agile Therapeutics Partners With Telehealth Platforms To Expand Access To Weekly Birth Control Patch To Millions Of Women
Tickers AGRX
Tags AGRX Agile Therapeutics Penny Stocks
From Benzinga
Agile Sees Renewed Hope For Even Broader Adoption Of Its Weekly Birth Control Patch After Biden's Latest Executive Order Expanding Contraceptive Coverage
Tickers AGRX
Tags Penny Stocks Benzinga AGRX
From Benzinga
H.C. Wainwright Reiterates Buy Rating For Agile Therapeutics (NASDAQ: AGRX), Citing Growing Demand For Twirla, A Weekly Low Dose Birth Control Patch
Tickers AGRX
Tags Analyst Ratings Markets Market News
From Benzinga
This Women's Healthcare Company Raised $7.5 Million In A Public Offering And Says It's Targeting $25 To $30 Million Net Revenue By End Of 2023
Tickers AGRX
Tags Partner Content Market News General
From Benzinga
Agile Therapeutics – This Women's Healthcare Company's "Skinfusion" Technology Sets It Apart From Other Contraceptive Companies
Tickers AGRX
Tags AGRX Agile Therapeutics Penny Stocks
From Benzinga
Agile Therapeutics Expects Its Innovative Once-A-Week Birth Control Patch To Drive Revenues Of $25-30 Million In 2023 – What Is The Hype All About?
Tickers AGRX
Tags Partner Content Market News General
From Benzinga
The Overturning of Roe v. Wade Has Changed The Landscape Of Birth Control; Smaller Companies Are Now An Integral Part Of Care
Tickers AGRX
Tags General Market News Partner Content
From Benzinga
Agile Therapeutics: The CEO Of This Women's Healthcare Company That Recently Saw Revenue Growth Of 33% Speaks To Benzinga
Tickers AGRX
Tags Benzinga Health Care AGRX
From Benzinga
Agile Therapeutics: This BioPharma Firm Is Nimbly Solving Unmet Needs For Women
Tickers AGRX
Tags Market News General AGRX
From Benzinga
This Biotech Company is Pursuing Positive Cash Flow In 2023
Tickers AGRX CVS
Tags Partner Content Market News General
From Benzinga
Women's Healthcare Company Agile Therapeutics Says It Believes It Has An Effective Business Plan In Place For Growth And Generating Positive Cash Flow
Tickers AGRX DARE HOLX
Tags AGRX HOLX Agile Therapeutics
From Benzinga
Can This Company's Birth Control Patch Disrupt The Contraceptive Market?
Tickers AGRX DARE
Tags Health Care Benzinga Penny Stocks
From Benzinga
The Past Week's Notable Insider Buys Included Digitalbridge, Life Time, A SPAC And More
Tickers AGRX DBRG LOKB LTH
Tags IMPAC Mortgage Life Time Benzinga
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.